Loading clinical trials...

COMPLETED

Efficacy and Tolerability of Enstilar® in Daily Practice

Prospective, Observational, Non-interventional, Multicenter Study on the Efficacy and Tolerability of Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in Patients With Plaque Psoriasis Under Daily Practice Conditions

NCT02881346•LEO Pharma

View on ClinicalTrials.gov

Summary

This study aims to assess how the Enstilar® aerosol foam performs in daily real-life practice with regards to effectiveness and convenience of application to psoriasis plaques on body and extremities. In addition the profiles of patients prescribed Enstilar® will be described, and preceeding, concomitant and follow-up management will be mapped. The study will be conducted in about 100 dermatology clinics all over Germany,

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•≥ 18 years of age
•Psoriasis vulgaris
•Lesions on trunk and/or extremities of at least mild severity
•Treatment with Enstilar® planned
•Signed informed consent to participate

Exclusion Criteria

•Enrolled in any interventional clinical trial
•Ongoing or recent treatment with any systemic psoriasis
•Ongoing or recent treatment with UV-therapy
•Ongoing or previous treatment with Enstilar®
•Psoriasis of scalp only
•Other forms of psoriasis, e.g. erythrodermic or pustular psoriasis
•More than 30% of surface area affected by psoriasis
•Any contraindications or known allergies to Enstilar® or its ingredients
•Incapacitated patients under institutionalized care

Locations (1)

Clinic for Dermatology, Venereology and Allergy, University Clinic Schleswig-Holstein

Kiel, Germany

Key Dates

Start Date

September 1, 2016

Primary Completion Date

March 1, 2017

Completion Date

March 1, 2017

Last Updated

December 13, 2019

Enrollment

410

ACTUAL participants

Conditions

Plaque Psoriasis

Interventions

Enstilar®

DRUG

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967

Plaque Psoriasis

View study

RECRUITINGPHASE3

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802

Plaque Psoriasis

View study

RECRUITINGPHASE2

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

NCT07449702

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 13, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy and Tolerability of Enstilar® in Daily Practice

Inclusion Criteria

Exclusion Criteria

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis